Nothing Special   »   [go: up one dir, main page]

DK3331885T3 - Forbindelser - Google Patents

Forbindelser Download PDF

Info

Publication number
DK3331885T3
DK3331885T3 DK16747519.3T DK16747519T DK3331885T3 DK 3331885 T3 DK3331885 T3 DK 3331885T3 DK 16747519 T DK16747519 T DK 16747519T DK 3331885 T3 DK3331885 T3 DK 3331885T3
Authority
DK
Denmark
Prior art keywords
connections
Prior art date
Application number
DK16747519.3T
Other languages
English (en)
Inventor
Stephen Brand
Petergeorge Dodd
Eun Jung Ko
Martin Maria Marco
Timothy James Miles
Lars Henrik Sandberg
Michael George Thomas
Stephen Thompson
Original Assignee
Glaxosmithkline Ip Dev Ltd
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, Univ Dundee filed Critical Glaxosmithkline Ip Dev Ltd
Application granted granted Critical
Publication of DK3331885T3 publication Critical patent/DK3331885T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK16747519.3T 2015-08-07 2016-08-03 Forbindelser DK3331885T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382418 2015-08-07
PCT/EP2016/068592 WO2017025416A1 (en) 2015-08-07 2016-08-03 Compounds

Publications (1)

Publication Number Publication Date
DK3331885T3 true DK3331885T3 (da) 2021-01-18

Family

ID=53887051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16747519.3T DK3331885T3 (da) 2015-08-07 2016-08-03 Forbindelser

Country Status (25)

Country Link
US (1) US10479792B2 (da)
EP (1) EP3331885B1 (da)
JP (1) JP6838045B2 (da)
KR (1) KR102652898B1 (da)
CN (1) CN108137599B (da)
AR (1) AR105606A1 (da)
AU (1) AU2016307230B2 (da)
BR (1) BR112018002597B1 (da)
CA (1) CA2994997C (da)
CY (1) CY1124151T1 (da)
DK (1) DK3331885T3 (da)
ES (1) ES2856899T3 (da)
HR (1) HRP20210402T1 (da)
HU (1) HUE052932T2 (da)
IL (1) IL257336B (da)
LT (1) LT3331885T (da)
MY (1) MY197042A (da)
PL (1) PL3331885T3 (da)
PT (1) PT3331885T (da)
RS (1) RS61434B1 (da)
RU (1) RU2734877C2 (da)
SI (1) SI3331885T1 (da)
TW (1) TWI746454B (da)
WO (1) WO2017025416A1 (da)
ZA (1) ZA201800733B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA039324B1 (ru) * 2017-11-06 2022-01-13 Новартис Аг 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
RU2717960C1 (ru) * 2019-08-05 2020-03-27 Федеральное Государственное бюджетное учреждение "27 Научный центр" Министерства обороны Российской Федерации СПОСОБ ПОЛУЧЕНИЯ ЗАМЕЩЕННЫХ α-БРОМАРИЛАЦЕТАЛЬДЕГИДОВ С ИСПОЛЬЗОВАНИЕМ БРОМИДА МЕДИ (II)
WO2024077273A2 (en) * 2022-10-07 2024-04-11 Denali Therapeutics Inc. Compounds, compositions, and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059418A1 (en) * 2008-11-19 2010-05-27 The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services Substituted triazine and purine compounds, methods of inhibiting cruzain and rhodesain and methods of treating chagas disease and african trypanosomiasis
BRPI1015949A2 (pt) * 2009-07-02 2016-04-26 Sanofi Sa derivados de 2,3-di-hidro-1h-imidazo [1,2-a] pirimidin-5-ona, o respectivo preparo e a respectiva utilização farmacêutica
WO2014151729A1 (en) * 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9233961B2 (en) * 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
DK3083627T3 (da) * 2013-12-19 2019-01-02 Novartis Ag [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis

Also Published As

Publication number Publication date
RU2734877C2 (ru) 2020-10-23
LT3331885T (lt) 2021-02-25
PT3331885T (pt) 2021-02-11
ES2856899T3 (es) 2021-09-28
US20180222911A1 (en) 2018-08-09
HRP20210402T1 (hr) 2021-04-16
US10479792B2 (en) 2019-11-19
IL257336A (en) 2018-03-29
EP3331885B1 (en) 2020-12-23
CY1124151T1 (el) 2022-05-27
SI3331885T1 (sl) 2021-03-31
CN108137599A (zh) 2018-06-08
KR20180043289A (ko) 2018-04-27
AU2016307230B2 (en) 2019-02-21
CA2994997C (en) 2023-10-10
HUE052932T2 (hu) 2021-05-28
JP6838045B2 (ja) 2021-03-03
RU2018107657A (ru) 2019-09-09
PL3331885T3 (pl) 2021-06-14
WO2017025416A1 (en) 2017-02-16
BR112018002597B1 (pt) 2020-09-24
AU2016307230A1 (en) 2018-02-22
TWI746454B (zh) 2021-11-21
TW201718590A (zh) 2017-06-01
RS61434B1 (sr) 2021-03-31
BR112018002597A8 (pt) 2020-04-07
MY197042A (en) 2023-05-22
JP2018522058A (ja) 2018-08-09
ZA201800733B (en) 2019-07-31
RU2018107657A3 (da) 2019-11-21
KR102652898B1 (ko) 2024-04-01
EP3331885A1 (en) 2018-06-13
AR105606A1 (es) 2017-10-18
IL257336B (en) 2020-11-30
CN108137599B (zh) 2020-10-27
CA2994997A1 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
NL301287I2 (nl) retifanlimab
FIC20230012I1 (fi) Teklistamabi
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
DK3305788T3 (da) Janus-kinase-hæmmer
DK3277719T3 (da) Polypeptider
DK3360890T3 (da) Genterapi
DK3331528T3 (da) Muskarinagonister
DK3331529T3 (da) Muskarinagonister
DK3310450T3 (da) Olie-vand-separator
DK3464336T3 (da) Forbindelser
DK3270930T3 (da) Præeklampsi
DK3362444T3 (da) Forbindelser
DK3394281T3 (da) Gærcelle
DK3292136T3 (da) Penicillin-g-acylaser
DE112015006486A5 (de) Inkubationsrinne
DK3274482T3 (da) Stenborsknop
DK3331885T3 (da) Forbindelser
DK3318308T3 (da) Badmintonketsjer
DE112015005905A5 (de) Gurtschlossbringer
DE112016005599A5 (de) Strahlungsgrill
ES1140083Y (es) Descompatactador tetrafunción
DE102015206660A8 (de) Plattenaufteilanlage
DE112016001124A5 (de) Spannschutz
FI11070U1 (fi) Kantojyrsin